Abstract:The promise of nicotinic receptors as a therapeutic target has yet to be fully realized, despite solid data supporting their involvement in neurological and neuropsychiatric diseases. The reasons for this are likely complex and manifold, having to do with the widespread action of the cholinergic system and the biophysical mechanism of action of nicotinic receptors leading to fast desensitization and down-regulation. Conventional drug development strategies tend to focus on receptor subtype-specific action of candidate therapeutics, although the broad agonist, nicotine, is being explored in the clinic. The potential negative effects of nicotine make the search for alternate strategies warranted. Prototoxins are a promising yet little-explored avenue of nicotinic receptor drug development. Nicotinic receptors in the brain belong to a complex of proteins, including those that bind to the extracellular face of the receptor, as well as chaperones that bind the intracellular domain, etc. Lynx prototoxins have allosteric modularity effects on receptor function and number and have been implicated in complex in vivo processes such as neuroplasticity, learning, and memory. Their mechanism of action and binding specificity on sets of nAChR subtypes present intriguing possibilities for more efficacious and nuanced therapeutic targeting than nicotinic receptor subtypes alone. An allosteric drug may restrict its actions to physiologically relevant time points, which tend to be correlated with salient events which would be encoded into long-term memory storage. Rather than blanketing the brain with a steady and prolonged elevation of agonist, an allosteric nAChR compound could avoid side effects and loss of efficacy over time. This review details the potential strengths and challenges of prototoxin proteins as therapeutic targets, and some of the utility of such therapeutics based on the emerging understanding of cholinergic signaling in a growing number of complex neural processes.

Toxins for decoding interface selectivity in nicotinic acetylcholine receptors

Structure-Function of Neuronal Nicotinic Acetylcholine Receptor Inhibitors Derived From Natural Toxins

Diverse toxins exhibit a common binding mode to the Nicotinic Acetylcholine Receptors revealing a new molecular determinant

Molecular modeling and structural analysis of nAChR variants uncovers the mechanism of resistance to snake toxins

Alpha-Conotoxins Active At Alpha 3-Containing Nicotinic Acetylcholine Receptors And Their Molecular Determinants For Selective Inhibition

Lynx1 and the family of endogenous mammalian neurotoxin-like proteins and their roles in modulating nAChR function

High Selectivity Of An Alpha-Conotoxin Lvia Analogue For Alpha 3 Beta 2 Nicotinic Acetylcholine Receptors Is Mediated By Beta 2 Functionally Important Residues

Key Structural Determinants in the Agonist Binding Loops of Human β2 and β4 Nicotinic Acetylcholine Receptor Subunits Contribute to α3β4 Subtype Selectivity of α-Conotoxins.

Nicotinic acetylcholine receptor modulator insecticides act on diverse receptor subtypes with distinct subunit compositions.

Identification of a Novel O-Conotoxin Reveals an Unusual and Potent Inhibitor of the Human Α9α10 Nicotinic Acetylcholine Receptor.

Species Specificity of Rat and Human Α7 Nicotinic Acetylcholine Receptors Towards Different Classes of Peptide and Protein Antagonists

Interaction of Rat Α9α10 Nicotinic Acetylcholine Receptor with Α-Conotoxin RgIA and Vc1.1: Insights from Docking, Molecular Dynamics and Binding Free Energy Contributions

Naturally occurring and synthetic peptides acting on nicotinic acetylcholine receptors

Structural Basis of Agonist Selectivity for Different Nachr Subtypes: Insights from Crystal Structures, Mutation Experiments and Molecular Simulations

Molecular Recognition Properties of Nicotinic Ligands Determining Selectivity Between Insect and Mammalian Receptors

Atypical Α-Conotoxin LtIA from Conus Litteratus Targets a Novel Microsite of the Α3β2 Nicotinic Receptor

Conotoxin Αd-Gexxa Utilizes a Novel Strategy to Antagonize Nicotinic Acetylcholine Receptors.

Computational determination of the binding mode of α-conotoxin to nicotinic acetylcholine receptor

Αo-Conotoxin GeXIVA Disulfide Bond Isomers Exhibit Differential Sensitivity for Various Nicotinic Acetylcholine Receptors but Retain Potency and Selectivity for the Human Α9α10 Subtype

α*-Conotoxins Targeting Nicotinic Acetylcholine Receptors

The Cyclic Imine Core Common to the Marine Macrocyclic Toxins Is Sufficient to Dictate Nicotinic Acetylcholine Receptor Antagonism